2x Your Donation
Double your impact on the team working to end Parkinson's by Thursday, December 31.
Learn More
Grant Programs
PDF has opened eight programs that provide critical funding for Parkinson's research.
Learn MoreEnding Parkinson's
PDF is increasing investment in research, health care and patient leaders, then mobilizing them to work together toward the cure.
Learn MoreA New Home for Parkinson's Science
An open access journal, enabling professionals and people with PD to access the latest research.
Learn MoreSlowing PD
PDF-funded scientist-clinician Oren Levy, M.D., Ph.D., wants to slow Parkinson's and he has already found some clues.
Learn MoreYour Donations Make a Difference
Your support makes the research of Dr. Hess and Dr. Earhart possible, allowing us to learn about the role of genetics and the potential of exercise in Parkinson's.
Watch Our Video & Learn More
Rapamycin Prevents Mitochondrial Dysfunction and PD Symptoms in Mouse Model
November 13, 2015
Research published September 16 in the Journal of Neuroscience finds that the drug rapamycin, an immunosuppressant drug already approved by the FDA for transplant patients, can protect brain cells and mitochondria, and ease movement symptoms in a mouse model of Parkinson’s disease (PD). Several years back, previous studies by a team at the PDF Research Center at Columbia University Medical Center, paved the way for this research by establishing the importance of rapamycin as a molecule of interest in PD therapies.
Parkinson's News
PD ExpertBriefing: Anxiety in Parkinson's
Tuesday, January 5 (Online)
Did you know that anxiety is a common symptom of PD? The good news is that there are strategies that people with PD can use to cope with its debilitating effects. Learn more by joining a one-hour online seminar led by PDF and Joseph H. Friedman, M.D., Director, Movement Disorders Program, Butler Hospital and Professor and Chief, Division of Movement Disorders, Warren Alpert Medical School, Brown University.
